Charles River Laboratories International Stock Price and Value Analysis

Charles River Laboratories International (NYSE:CRL) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Charles River Laboratories International to reach your target.

Target type

CRL Free Cash Flow Trend

Free Cash Flow trendline for CRL
Free Cash Flow trendline for Charles River Laboratories International
CSV

Based on historical returns, we believe that Charles River Laboratories International can grow its free cash at a rate of about 6%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company has stable growth.
  • This company is making money at a decent rate.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company pays no dividend.

Inside the CRL Numbers

CRL Price
(Charles River Laboratories International stock price per share)
$314.32
[?] CRL Fair Price
(based on intrinsic value)
$184.68
[?] CRL Safety Price (based on a variable margin of safety) $110.81
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 1586% higher than other Healthcare stocks
[?] PE Ratio versus Industry 78% lower than other Diagnostics & Research stocks
[?] Cash Yield 2.12%
[?] Free Cash Flow Jitter 19%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 2,987,094 shares shorted. With 47,415,771 shares available for purchase and an average trading volume over the past 10 trading days of 780,840, it would take at least 3.8 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2008 1100682 76.9
2009 1100682 76.3
2010 1100682 61.1
2011 1100682 114
2012 1100682 124
2013 1100682 157
2014 1100682 205
2015 1100682 256
2016 1100682 264
2017 1100682 259
2018 1100682 362
2019 1100682 385
2020 1100682 430
2021 1100682 609
2022 1100682 420
2023 1100682 448
2024 1100682 480
2025 1100682 473

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 13 fiscal years from 2008 to 2025 with positive net income, operating cash flow totaled $5,886 million against net income of $2,988 million, or 1.97 times. Net income was negative in 3 of the 16 years, and those years are left out of the ratio.

In 2025, net income was -$144 million and operating cash flow was $738 million, so no ratio is shown for that year.

In 2025, capital expenditures were $219 million, 29.7% of operating cash flow of $738 million, which leaves an estimated $518 million after capex. Across the 16 years with reported capex, it averaged 33.8% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2008 -525 276 199 n/a
2009 114 216 79.9 1.88
2010 -337 168 42.9 n/a
2013 103 209 39.2 2.03
2014 127 252 56.9 1.99
2015 149 307 63.3 2.05
2016 155 317 55.3 2.05
2017 123 318 82.4 2.58
2018 226 441 140 1.95
2019 252 481 141 1.91
2020 364 547 167 1.50
2021 391 761 229 1.95
2022 486 620 325 1.27
2023 475 684 319 1.44
2024 22.2 735 233 33.08
2025 -144 738 219 n/a

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $4,129 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 7 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $714 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, cash spent repurchasing shares was $361 million, 76.3% of estimated free cash flow of $473 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 264 n/a 12.3 12.3 4.6%
2017 259 n/a 107 107 41.3%
2018 362 n/a 13.8 13.8 3.8%
2019 385 n/a 18.1 18.1 4.7%
2020 430 n/a 24 24 5.6%
2021 609 n/a 40.7 40.7 6.7%
2022 420 n/a 38.7 38.7 9.2%
2023 448 n/a 24.2 24.2 5.4%
2024 480 n/a 119 119 24.8%
2025 473 n/a 361 361 76.3%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $1,295 million in 2008 and $4,015 million in 2025, a compound annual growth rate of 6.9% over 17 years.

Revenue fell 0.9% from 2024 to 2025.

Our estimated free cash flow was $473 million in 2025, 11.8% of revenue. In 2008 the estimated margin was 5.9%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2008 1,295 76.9 5.9%
2009 1,172 76.3 6.5%
2010 1,133 61.1 5.4%
2011 1,143 114 10.0%
2012 1,130 124 11.0%
2013 1,166 157 13.5%
2014 1,298 205 15.8%
2015 1,363 256 18.8%
2016 1,681 264 15.7%
2017 1,858 259 13.9%
2018 2,266 362 16.0%
2019 2,621 385 14.7%
2020 2,924 430 14.7%
2021 3,540 609 17.2%
2022 3,976 420 10.6%
2023 4,129 448 10.9%
2024 4,050 480 11.9%
2025 4,015 473 11.8%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $214 million against total liabilities of $3,924 million, or 5.4% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 55.0% of total assets in 2025, compared with 68.8% in 2009, a decrease of 13.8 percentage points.

Stockholders equity was $3,170 million in 2025, compared with $1,374 million in 2009, a rise of 130.7%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 8.2% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2009 2,204 183 1,515 1,374
2010 1,733 179 1,206 689
2011 1,558 68.9 1,031 527
2012 1,586 110 983 603
2013 1,633 156 968 644
2014 1,871 160 1,166 676
2015 2,068 118 1,303 738
2016 2,712 118 1,847 839
2017 2,930 164 1,866 1,047
2018 3,856 195 2,518 1,320
2019 4,693 238 3,026 1,638
2020 5,491 228 3,347 2,118
2021 7,024 241 4,432 2,539
2022 7,603 234 4,579 2,981
2023 8,195 277 4,536 3,602
2024 7,528 195 4,020 3,467
2025 7,135 214 3,924 3,170

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $314.32, our model's value equals that price if free cash flow grows an average of 16.2 percent a year over the 10 projection years. Our model assumes 6.2 percent a year for this stock, so the price implies growth of 16.2 percent, which is above the 6.2 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $320 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $251.46 12.2%
Current price $314.32 16.2%
20 percent above the current price $377.18 19.3%
Our model (stored fair price) $184.68 6.2%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Every one of the 18 fiscal years we have for Charles River Laboratories International under its current filer shows positive free cash flow.

At $314.32, the price is above our fair value estimate of $184.68 for Charles River Laboratories International.

Comparing the first and last three years of data, average free cash flow rose sharply: $71.5 million at the start and $467 million most recently.

Year-to-year variability in free cash flow is fairly steady, measured at 19%.

Dividends are not in our data for Charles River Laboratories International.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 1586% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 78% below the average for stocks in the Diagnostics & Research industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Diagnostics & Research industry, the ones closest in market capitalization to Charles River Laboratories International, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Charles River Laboratories International (CRL) 15,061 341.7 - 2.1% 70% above
Medpace Holdings (MEDP) 17,078 33.9 - - 3621% above
Incyte Corporation (INCY) 23,364 58.5 - 0.6% 166% above
Lantheus Holdings (LNTH) 6,677 25.4 - - 513% above
RadNet (RDNT) 5,491 - - 1.4% 42% below
Quest Diagnostics Incorporated (DGX) 28,416 25.7 1.3% 3.0% 25% above
National Research Corporation (NRC) 534 93.2 2.6% - 3712% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1100682.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: CRL annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in CRL

Does Charles River Laboratories International have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: CRL

This example shows how we apply the Trendshare checklist to CRL: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 314.32
    • Market cap: $15B
    • EPS: 0.92
  2. Step 2 — Valuation checks

    • P/E: 341.652
    • FCF yield: 2.1%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.